Tom Powles: Belzutifan for clear cell renal cancer

Tom Powles shared a post on X:

“Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer. Toni Choueiri, Brian Rini, Laurence Albiges high Response Rate (RR), Progression Free Survival (PFS), Quality of Life (QOL) but no Overall Survival (OS). Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited.”

Source: Tom Powles/X

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.